Opko Health, Inc. - Aug 15, 2024 Form 4 Insider Report for GeneDx Holdings Corp. (WGS)

Role
10%+ Owner
Signature
Steven D. Rubin, Exec. VP - Administration
Stock symbol
WGS
Transactions as of
Aug 15, 2024
Transactions value $
-$4,756,875
Form type
4
Date filed
8/19/2024, 05:23 PM
Previous filing
Aug 14, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WGS Class A Common Stock Sale -$1.32M -39.8K -1.43% $33.08 2.75M Aug 15, 2024 Direct F1
transaction WGS Class A Common Stock Sale -$1.71M -50K -1.82% $34.30 2.7M Aug 16, 2024 Direct F2
transaction WGS Class A Common Stock Sale -$1.72M -50K -1.85% $34.49 2.65M Aug 19, 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Opko Health, Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $34.26, inclusive. The reporting person undertakes to provide to GeneDx Holding Corp. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (1) to this Form 4.
F2 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.84 to $34.86, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (2) to this Form 4.
F3 The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.00 to $35.53, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote (3) to this Form 4.